Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
NCT07674745
Disease Attributes, Disease Progression
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT07404423
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with marked inter-individual heterogeneity in trajectories and outcomes. Despite antifibrotic therapies, reliable risk stratification in routine practice remains suboptimal. OPEN-IPF is a multicentre retrospective observational cohort study designed to build a harmonised real-world dataset across Italian IPF referral centres to enable the development and external validation of machine-learning (ML) models predicting clinically relevant outcomes.
Trial opening soon.
Get Notified18 year–90 year
All sexes
Observational
OPEN-IPF addresses the current limitation of AI/ML research in IPF-namely, the lack of large multicentre real-world datasets with harmonised variables and robust external validation. The study will retrospectively include adult patients with IPF followed in routine practice in participating Italian referral centres from 1 January 2015 to 31 December 2025 (data lock). No study-specific procedures will be performed. De-identified/pseudonymised data will be collected using a common data model, including demographics, smoking history, comorbidities, pulmonary function (FVC, DLCO), oxygen requirement, 6-minute walk test (where available), antifibrotic treatment exposure, HRCT features routinely reported, basic laboratory parameters, and clinical outcomes. The primary modelling targets are disease progression, acute exacerbations of IPF (AE-IPF), and real-world response to antifibrotic treatment. Model development will be performed using multicentre data with explicit external validation across centres
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From baseline (index date) up to 12 months and up to end of available follow-up (maximum: 31 December 2025)
Disease progression defined using guideline-based criteria derived from routinely collected clinical data (e.g., decline in lung function and/or composite progression definitions as per the shared operational document).
Time frame: From baseline to end of follow-up (maximum: 31 December 2025)
Occurrence of AE-IPF during follow-up, adjudicated from routine clinical documentation using standardised operational definitions shared across centres.
Time frame: From treatment initiation (or baseline if already treated) up to 12 months and end of follow-up (maximum: 31 December 2025)
Treatment response assessed in routine clinical practice using longitudinal clinical/functional data and treatment exposure information (type, start, discontinuation)
Time frame: From baseline to end of follow-up (maximum: 31 December 2025)
Time from baseline to death from any cause.
Time frame: From baseline to end of follow-up (maximum: 31 December 2025)
Time from baseline to lung transplantation or death.
Time frame: From baseline to end of follow-up (maximum: 31 December 2025)
Time from baseline to first occurrence of disease progression or AE-IPF.
Contact information is provided by the study sponsor or research team.
Roberto Tonelli, MD, PhD
CONTACT
Stefania Cerri, MD, PhD
CONTACT
University of Modena and Reggio Emilia
Other
Observational Prediction Model for Clinical Outcomes in Idiopathic Pulmonary Fibrosis: a Multicentre, ML-driven Study (OPEN-IPF)
Acronym: OPEN-IPF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07674745
Disease Attributes, Disease Progression
Birmingham, Alabama, United States
View Trial DetailsNCT07728448
Cardiovascular Diseases, Connective Tissue Disease-associated Interstitial Lung Disease
View Trial DetailsNCT07723638
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
View Trial DetailsNCT07722507
Fibrosis, Idiopathic Pulmonary Fibrosis
Tokyo, Japan
View Trial Details